Highlights
• Record operating cash receipts for the quarter, totalling $1.32 million, an increase of 77% on the September quarter ($0.75 million)
• Strong operational performance across all key metrics o Over 600,000 users on the MedAdvisor platform as at 31 December 2016, an increase of over 160% since September 2016
o Over 45% of Australian pharmacies connected to the platform (30% in September quarter 2016)
o Patient Engagement Programs (PEPs) experienced rapid traction, closing the quarter with 18 medications using the platform across 9 of Australia’s largest pharmaceutical companies including Pfizer, GSK, AstraZeneca, Novartis & Bristol-Myers Squibb
o Increased the number of General Practitioners (GPs) benefiting from the platform to nearly 4,000 GPs
o Tap-to-Refill script ordering function processing an average of $2.5 million in script refill value per week
• Completion of $8 million oversubscribed capital raising receiving strong participation from leading Australian financial institutions and pharmacy groups
• Completion of Healthnotes acquisition, significantly enhancing the MedAdvisor offering and expanding market share
• Key partnership agreements with Asthma Australia and Osteoporosis Australia, plus extended existing relationship with Bupa into certain Healthscope Hospitals
Add to My Watchlist
What is My Watchlist?
